How to Challenge a Patent at the UPC From the Netherlands (2026): Step‑by‑step for Chemical & Biotech Companies

Challenge patent UPC Netherlands actions have become a central strategic tool for Dutch chemical and biotech companies seeking to clear competitor rights across Europe in a single proceeding. Since the Unified Patent Court (UPC) opened its doors on 1 June 2023, revocation (nullity) actions have offered a judicial route to invalidate a European patent with binding effect across the participating Member States in which the patent has effect, rather than fighting parallel national battles. In 2026, rising filing volumes and a maturing body of case law have sharpened the question every in‑house IP counsel now faces: when should a Netherlands‑based business pursue central revocation at the UPC, and how exactly is it done?

This guide sets out the procedure, timelines, evidence requirements and realistic costs, written for in‑house IP counsel, R&D managers, founders and SME management in the Dutch chemical and life‑sciences sector.

Search intent, who this is for

• Who this is for. In‑house IP counsel, R&D managers, founders and Netherlands‑based biotech and chemical SMEs assessing or planning a UPC revocation.
• What this covers. Eligibility, step‑by‑step filing and service, evidence assembly for chemical and biotech patents, estimated timelines and costs (2026), representation rules for the Netherlands, and a tactical comparison with EPO opposition.
• What this does not cover. Full trial advocacy training or an infringement‑defence tactical deep‑dive (covered in separate guidance).

Key takeaways

A decision to challenge patent UPC Netherlands rights should always begin with a realistic assessment of the prior art and the technical strength of your invalidity case before a single document is filed. The UPC offers a powerful central remedy, but it is a judicial forum with court‑managed evidence, structured deadlines and costs that can run from tens of thousands to well over a million euros in complex chemical or biotech matters. Choosing between an EPO opposition and a UPC revocation is a strategic question driven by speed, cost, remedy and the geography of your commercial risk. For Dutch businesses, early budgeting, disciplined evidence preservation and selection of a UPC‑authorised representative are the three decisions that most influence outcome.

Whether a particular country is “best” for intellectual property enforcement depends entirely on the facts, the real question is which forum fits your risk profile.

1. Overview, what a UPC revocation (nullity) action covers

A revocation action asks the UPC to declare that a European patent (or a European patent with unitary effect) is invalid and should be struck out. Unlike a national nullity action confined to one country, a successful central revocation at the UPC removes the patent across the participating Member States in which the patent has effect in a single judgment, which is precisely why the forum matters so much for companies operating across European markets. For a classic (non‑unitary) European patent, the territorial reach of a UPC revocation depends on the Member States for which the patent was validated and which have not been opted out of the UPC system.

When you challenge patent UPC Netherlands rights through this route, you are seeking a judicial determination with potentially pan‑European reach.

Legal basis (UPCA and Rules of Procedure)

The UPC’s jurisdiction and powers derive from the Agreement on a Unified Patent Court (UPCA), supplemented by the Court’s Rules of Procedure. These instruments set out who may bring an action, the grounds on which a patent may be revoked, and the procedural framework governing pleadings, evidence and timetables. The standard grounds mirror substantive European patent law: lack of novelty, lack of inventive step, insufficiency of disclosure, added subject matter, extension of the protection conferred, and excluded or non‑patentable subject matter.

Remedies available

The principal remedy is revocation, in whole or in part, of the patent. The Court may also award costs to the successful party within prescribed ceilings, and in appropriate cases grant declaratory relief such as a declaration of non‑infringement. For a chemical or biotech company facing commercial exposure, the decisive benefit is that central revocation can eliminate the patent as a barrier across the relevant UPC territory at once, rather than leaving residual national rights in force.

2. Eligibility & representation, who can bring a revocation and how to be represented

Understanding standing and representation is the foundation of any decision to challenge patent UPC Netherlands rights. The rules are set out in the UPCA and Rules of Procedure, and they differ in important respects from Dutch national court practice.

Standing and party types

A standalone revocation action before the UPC may generally be brought by any natural or legal person, or any body entitled to bring actions under the applicable law, who is affected by the patent. In practice, the typical claimant is an alleged infringer seeking to clear the way, a competitor planning market entry, or a third party exposed to the patent. A revocation claim may also arise as a counterclaim within infringement proceedings. For Dutch companies, cross‑border considerations matter: a business headquartered in the Netherlands can bring a central revocation targeting a patent that creates risk across the UPC territory, not merely in the Netherlands.

Representation rules for Netherlands‑based parties, who may appear

Parties before the UPC must be represented. Representation may be undertaken by lawyers authorised to practise before a court of a Contracting Member State, or by European Patent Attorneys who hold an appropriate litigation qualification (the European Patent Litigation Certificate or another qualification recognised under the applicable Rules). This addresses a common question, can a foreigner act as a lawyer in the Netherlands? For UPC purposes, the relevant qualification is authorisation to act before the UPC, which is not confined to members of the Dutch Bar (Nederlandse Orde van Advocaten). A Netherlands‑based company can therefore instruct a UPC‑authorised representative who is qualified in any Contracting Member State, often working alongside local Dutch counsel for enforcement and national‑law questions.

Where a matter touches on Dutch national proceedings, Dutch Bar rules on admission and rights of audience continue to apply.

Emergency relief and preliminary measures

A revocation applicant is usually in a defensive posture rather than seeking injunctions, but the UPC can order provisional and protective measures in appropriate cases. A party anticipating an infringement claim may, for example, combine a revocation action with a request for a declaration of non‑infringement. Understanding the interplay between offensive and defensive measures early allows you to shape the forum and timing of the dispute before the patent proprietor seizes the initiative.

3. Step‑by‑step procedure, how to file a revocation at the UPC

This is the operational core of any plan to challenge patent UPC Netherlands rights. The process below is presented as a sequence of twelve stages. Each stage identifies what must be done, who leads, and a realistic timing expectation, followed by practical commentary for chemical and biotech matters.

1. Pre‑filing assessment. Conduct a thorough prior art search, build a preliminary claim chart mapping each claim against the closest prior art, run a freedom‑to‑operate review, and examine the EPO file wrapper (including prosecution history and any divisional applications). This stage determines whether a case exists at all. Lead: in‑house counsel with external litigator and a technical expert. Timing: 2–6 weeks.
2. Strategy decision, EPO opposition or UPC revocation. Decide the forum. If the patent is within the nine‑month opposition window and you have clear invalidating prior art, an EPO opposition may be more cost‑effective; if central judicial removal across Member States is decisive or multiple national courts could become active, UPC revocation is usually preferable. Note that a classic European patent may need to be checked for any opt‑out from the UPC’s jurisdiction. Lead: senior IP counsel with external litigator. Timing: 1–2 weeks.
3. Selecting the registry and division. Standalone revocation actions are allocated to the Central Division, which has seats in Paris and Munich (together with a section handling further technical fields) with defined technical field allocations. For chemical and biotech patents, the technical allocation of the panel matters because the judges and technically qualified members shape how expert evidence is received. Lead: UPC counsel. Timing: folded into drafting.
4. Preparing the revocation application. Draft the statement for revocation and relief sought, assemble evidence bundles, finalise claim charts, commission expert statements, apply any necessary redactions, and propose a confidentiality regime where sensitive technical data is involved. This is the most intensive drafting stage. Lead: UPC litigator with patent attorney and expert. Timing: 2–4 weeks.
5. Filing the application. File through the UPC Case Management System, completing all required fields, attaching the power of attorney, and paying the official fee. The filing date (Day 0) triggers the procedural calendar. Lead: UPC counsel. Timing: filing day.
6. Service and any provisional measures. The application is served on the patent proprietor in accordance with the Rules of Procedure. If provisional measures are sought, they are applied for at or near this point. Lead: counsel for the serving party. Timing: 1–4 weeks after filing.
7. Case management and timetable order. The judge‑rapporteur manages the written and interim procedure, including deadlines for the defence, reply, and expert evidence. Lead: UPC judge(s). Timing: following completion of the written exchange of pleadings.
8. Evidence exchange and the written procedure. Parties exchange written pleadings, witness statements and expert reports. The UPC operates a largely front‑loaded, court‑managed evidence model rather than extensive common‑law‑style discovery. The Court may order production of specific evidence or inspection in defined circumstances. Lead: parties and experts. Timing: 3–6 months.
9. Interim conference and provisional measures. Any applications for provisional or protective measures are heard, and an interim conference may be held to prepare for the oral hearing. For a revocation claimant this is usually defensive, but it can be material where the proprietor has threatened or commenced infringement proceedings. Lead: parties and judge. Timing: variable, 1–6 months if applied for.
10. Oral hearing. The Court hears oral argument and, where ordered, witness and expert testimony. In chemistry and biotech cases, expert evidence on reproducibility, data interpretation and the person skilled in the art is often decisive, so hearing preparation must focus on presenting technical experiments clearly. The UPC aims to conclude the oral hearing within roughly one year of the action starting, though complex matters can take longer. Lead: parties, counsel and experts. Timing: the hearing typically falls 6–14 months from filing, longer for complex matters.
11. Decision and enforcement. The panel delivers its decision, which the Court aims to issue in writing within about six weeks of the oral hearing. A central revocation takes effect across the participating Member States in which the patent has effect. An appeal may be lodged with the UPC Court of Appeal within the prescribed deadline. Lead: UPC panel. Timing: decision typically within weeks of the hearing, panel‑dependent.
12. Post‑decision steps. Pursue costs recovery within the applicable ceilings and address any enforcement or cross‑border implementation. Lead: counsel and, where national steps are needed, local courts. Timing: variable.

Chemical and biotech practice points within the procedure

Technical disputes in this sector turn on claim construction, reproducibility and data integrity. Where insufficiency of disclosure is pleaded, you will often need to demonstrate, by independent laboratory replication, that the patent does not enable the claimed invention across its scope. Sequence listings, deposit of biological material, and the admissibility of experimental data all require early planning. Expect to invest in experiments that are methodologically defensible and documented to a court‑ready standard.

Step / Who / Duration timeline (challenge patent UPC Netherlands)

4. Required documents, what to prepare and file

Preparation discipline separates a strong revocation case from a vulnerable one. Assemble the following before filing; chemical and biotech matters demand particular care over laboratory records and confidentiality.

5. Timeline & deadlines, what to expect and calendar risks

The UPC runs a front‑loaded, deadline‑driven process. The filing date sets the calendar in motion; thereafter, the written and interim procedures fix dates for the defence, reply, expert reports and the hearing. Missing a deadline can cost you the right to adduce evidence, so a litigation project plan with internal buffers is essential for any team that intends to challenge patent UPC Netherlands rights.

Chemical and biotech cases carry a particular calendar risk: where you rely on experimental replication, allow 8–12 weeks for experiments to be designed, run, repeated and written up to an admissible standard. Independent contract research organisations (CROs) book up, and rushed experiments are easy for an opponent’s expert to discredit. Build the experimental programme into your schedule before filing, not after the procedural timetable is set. The Step / Who / Duration table above should be used as your master calendar, with each duration converted into dated deadlines once the Court issues its orders.

6. Costs & fees, realistic estimates for Dutch chemical & biotech challengers

Budget realistically and in phases. Official UPC fees are only one component; counsel fees, expert reports and experimental reproduction usually dominate the spend in technical cases. The UPC applies a fixed fee for revocation actions plus, in certain situations, a value‑based fee; the figures below are illustrative ranges, not quotations, verify the current official fee against the UPC fee schedule before filing, and obtain a case‑specific estimate from counsel.

Plan funding in three phases: phase one for pre‑filing assessment, phase two for core proceedings and evidence, and phase three for the hearing and any expert examination. Note that the UPC applies ceilings to recoverable representation costs scaled by the value of the action, so even a successful party rarely recovers its full spend. In cross‑border disputes, be alert to the possibility of a security‑for‑costs order. These figures are illustrative, always obtain a tailored quotation.

7. What changes in 2026, Netherlands & UPC

For Dutch stakeholders asking what is new in 2026, the most significant developments are practical rather than foundational. Filing volumes have continued to rise, and a growing body of UPC first‑instance and Court of Appeal decisions has begun to clarify how the Court handles added‑matter, inventive‑step and insufficiency arguments, the grounds most relevant to chemical and biotech patents. This maturing jurisprudence makes case outcomes somewhat more predictable and strengthens the value of a well‑prepared central revocation.

Fee schedules and procedural details are kept under review and are published on the UPC’s official pages; any figure you rely on should be cross‑checked against the live schedule at the time of filing. Representation requirements remain governed by the UPCA and Rules of Procedure, with authorisation to act before the UPC the key credential for Netherlands‑based parties. The transitional period during which classic European patents may be opted out of the UPC’s jurisdiction continues to shape forum choices, so the opt‑out status of a target patent should always be checked. Where a dispute interacts with Dutch national enforcement, the general framework administered through the Dutch courts continues to apply.

Industry observers expect the trend toward central revocation to intensify as more patents fall within the UPC system and companies weigh the efficiency of a single pan‑European challenge against parallel national actions.

8. Tactical comparison, EPO opposition vs UPC revocation (how to choose)

Choosing the right forum is often more consequential than any single procedural step. The table below summarises the headline differences; the decision checklist that follows helps translate it into a choice for your matter.

As a short decision guide: prefer the EPO opposition route when the patent is still within the nine‑month opposition window, your prior art is strong and documentary, and cost sensitivity is high. Prefer a UPC revocation when you need binding judicial removal across Member States, when infringement risk in the Netherlands or elsewhere is live, or when speed to a definitive, enforceable outcome outweighs the higher cost. In some cases the two can be run in parallel, a strategy that requires careful coordination to avoid inconsistent positions and to manage any stay considerations.

9. Common pitfalls & practical tips for chemical and biotech cases

• Late evidence. The UPC is front‑loaded; evidence filed late may be excluded. Finalise expert reports and experiments before the timetable tightens.
• Under‑qualified experts. Choose an expert whose field matches the person skilled in the art; a mismatch undermines credibility on inventive step.
• Lost laboratory records. Preserve lab notebooks and raw data with a clear chain of custody from the outset, reconstructed records are vulnerable to challenge.
• Under‑budgeting experiments. Reproducibility testing is a common cost overrun in biotech matters; price it realistically.
• Weak claim charts. Map every challenged claim feature to specific prior art; vague mapping invites rejection of the attack.
• Confidentiality mishandling. Request confidentiality protection early where sensitive data is involved, before inadvertent disclosure forecloses the option.
• Using in‑house teams for independent experiments. Independent CROs lend objectivity; experiments run by an interested party may carry less weight.
• Overlooking sequence listings and deposits. For biotech patents, ensure sequence listings and any deposited material are addressed in the pleadings and evidence.
• Ignoring translation lead times. Certified translation of key documents takes longer than teams expect; schedule it in.
• Delaying forum choice. The EPO opposition window closes nine months after grant; decide early so you preserve both options.

Conclusion & next steps

To challenge patent UPC Netherlands rights successfully, Dutch chemical and biotech companies need three things in place from the start: a technically robust invalidity case built on preserved evidence, a deliberate forum choice between EPO opposition and UPC revocation, and a phased budget that reflects the real cost of expert and experimental work. The UPC’s central remedy is powerful, but it rewards preparation and punishes delay. If you are weighing a revocation or assessing your exposure to one, the sensible first move is a focused risk assessment by a UPC‑authorised representative before any deadline forces your hand.

For tailored guidance on how to challenge patent UPC Netherlands actions, review the Intellectual Property Lawyer Netherlands checklist (2026) and arrange a consultation through Global Law Experts. This article is general information, not legal advice; obtain advice specific to your matter before acting.

Related reading: When to choose EPO opposition vs UPC revocation (Netherlands); How to defend a UPC infringement claim in the Netherlands; Litigation budgets and funding options for SME patent disputes (Netherlands); Choosing a UPC‑authorised representative in the Netherlands.

Last updated: October 19, 2026.

Sources

1. Unified Patent Court (official site)
2. UPC, Rules of Procedure / Legal framework
3. UPC, Fees (official)
4. Agreement on a Unified Patent Court (UPCA)
5. European Patent Office, opposition and procedure guidance
6. European Patent Office, European Patent Convention (EPC)
7. Nederlandse Orde van Advocaten (Dutch Bar)
8. Rechtspraak (Dutch Courts official portal)